15 de diciembre de 2009 / 14:45 / hace 8 años

Array shares surge on Amgen partnership

Dec 15 (Reuters) - Shares of Array BioPharma Inc (ARRY.O) surged about 30 percent Tuesday, a day after the company said it inked a partnership deal with Amgen Inc (AMGN.O) for the development and marketing of its Type 2 diabetes drug.

Under the terms of the agreement, Array will receive an upfront payment of $60 million and additional milestone payments on its experimental glucokinase activator program, including ARRY-403.

The drug is currently being tested in an early-stage trial in patients with Type 2 diabetes.

As part of the deal, Amgen will have exclusive worldwide rights for the drug and will be responsible for future clinical development and commercialization of the drug.

Array will receive double-digit royalties on sales of ARRY-403, the company said in statement.

Shares of the company rose more than 30 percent at $2.95 in early morning trade on Nasdaq. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Anil D'Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below